File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Anti-obesity drug prescribing in children and adolescents: a population-based study in the UK

TitleAnti-obesity drug prescribing in children and adolescents: a population-based study in the UK
Authors
Keywordsobesity
anti-obesity drug
children
adolescents
general practice
Issue Date2013
PublisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62
Citation
The 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 133 How to Cite?
AbstractAim/Objectives: To investigate prescribing patterns of anti-obesity drugs (orlistat and sibutramine) to children and adolescent aged 0-18 years in the UK. Methods: Using the UK General Practice Research Database (GPRD), we carried out a retrospective cohort study between January 1999 and December 2006. The cohort comprised of all children and adolescents aged 0-18 years who received at least one antiobesity drug prescription. The overall, age, and sex-specifi c prevalence of prescribing was calculated. The duration of anti-obesity drug treatment was also analysed. Treatment was considered as stopped if there were no further prescriptions issued within 90 consecutive days after the date of the last prescription. The Kaplan-Meier survival analysis was used to investigate treatment duration. Results: A total of 452 subjects received 1333 prescriptions during the study period. The annual prevalence of anti-obesity drug prescriptions rose signifi cantly from 0.006 per 1000 (95 % CI :0.0007-0.0113) in 1999 to 0.091 per 1000 (95% CI: 0.07- 0.11) in 2006; a 15-fold increase. The sex-specifi c prevalence was signifi cantly increasing in both boys and girls over the study period (p<0.05). The use of orlistat accounted for the majority of anti-obesity drug prescriptions (78.4%). The mean duration of orlistat use was signifi cantly shorter (3.0 months; 95%CI: 2.72 to 3.47) compared with sibutramine (4.2 months; 95%CI: 3.4 to 5.0) (p=0.003). Approximately 45% of orlistat prescriptions were discontinued within the fi rst month and about 25% of sibutramine prescriptions were discontinued within the fi rst month. Conclusion: Prescribing of anti-obesity drugs in young people has dramatically increased during past few years. However, the majority of prescriptions are rapidly discontinued during the fi rst 3 months, suggesting tolerability and effectiveness may be low in routine clinical use. Further research into the effectiveness and safety of anti-obesity drugs in children and adolescents in a clinical population is needed.
DescriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia
Rising Star Session
Persistent Identifierhttp://hdl.handle.net/10722/204444
ISSN

 

DC FieldValueLanguage
dc.contributor.authorHsia, Yen_US
dc.contributor.authorNeubert, Aen_US
dc.contributor.authorViner, Ren_US
dc.contributor.authorWong, ICKen_US
dc.date.accessioned2014-09-19T23:52:21Z-
dc.date.available2014-09-19T23:52:21Z-
dc.date.issued2013en_US
dc.identifier.citationThe 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 133en_US
dc.identifier.issn1727-2874-
dc.identifier.urihttp://hdl.handle.net/10722/204444-
dc.descriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia-
dc.descriptionRising Star Session-
dc.description.abstractAim/Objectives: To investigate prescribing patterns of anti-obesity drugs (orlistat and sibutramine) to children and adolescent aged 0-18 years in the UK. Methods: Using the UK General Practice Research Database (GPRD), we carried out a retrospective cohort study between January 1999 and December 2006. The cohort comprised of all children and adolescents aged 0-18 years who received at least one antiobesity drug prescription. The overall, age, and sex-specifi c prevalence of prescribing was calculated. The duration of anti-obesity drug treatment was also analysed. Treatment was considered as stopped if there were no further prescriptions issued within 90 consecutive days after the date of the last prescription. The Kaplan-Meier survival analysis was used to investigate treatment duration. Results: A total of 452 subjects received 1333 prescriptions during the study period. The annual prevalence of anti-obesity drug prescriptions rose signifi cantly from 0.006 per 1000 (95 % CI :0.0007-0.0113) in 1999 to 0.091 per 1000 (95% CI: 0.07- 0.11) in 2006; a 15-fold increase. The sex-specifi c prevalence was signifi cantly increasing in both boys and girls over the study period (p<0.05). The use of orlistat accounted for the majority of anti-obesity drug prescriptions (78.4%). The mean duration of orlistat use was signifi cantly shorter (3.0 months; 95%CI: 2.72 to 3.47) compared with sibutramine (4.2 months; 95%CI: 3.4 to 5.0) (p=0.003). Approximately 45% of orlistat prescriptions were discontinued within the fi rst month and about 25% of sibutramine prescriptions were discontinued within the fi rst month. Conclusion: Prescribing of anti-obesity drugs in young people has dramatically increased during past few years. However, the majority of prescriptions are rapidly discontinued during the fi rst 3 months, suggesting tolerability and effectiveness may be low in routine clinical use. Further research into the effectiveness and safety of anti-obesity drugs in children and adolescents in a clinical population is needed.-
dc.languageengen_US
dc.publisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62-
dc.relation.ispartofHong Kong Pharmaceutical Journalen_US
dc.subjectobesity-
dc.subjectanti-obesity drug-
dc.subjectchildren-
dc.subjectadolescents-
dc.subjectgeneral practice-
dc.titleAnti-obesity drug prescribing in children and adolescents: a population-based study in the UKen_US
dc.typeConference_Paperen_US
dc.identifier.emailHsia, Y: yfhsia@hku.hken_US
dc.identifier.emailWong, ICK: wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.identifier.hkuros238779en_US
dc.identifier.volume20en_US
dc.identifier.issue3en_US
dc.identifier.spage133en_US
dc.identifier.epage133en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats